ER+/HER2+ Metastatic Breast Cancer

Hope S. Rugo, MD, looks at the use of CDK4/6 inhibitors for patients with metastatic ER-positive, HER2-positive breast cancer and the trials evaluating their use in this setting.

• শ্রেণী